NTI secures strategic Cultivation partnership to grow and maintain its medical cannabis
Neurotech International Limited (ASX:NTI) has announced a strategic cultivation partnership with CannaPacific Limited to grow and maintain genetic stock and assist in the development of elite varietal strains through their exclusive licencing agreement.
The partnership supports NTI as it prepares for expanded clinical studies in larger patient groups in calendar Q2/Q3, which will follow successful outcomes of the Phase I/II clinical trials that have begun this quarter.
Current trial parameters are intended to form the basis for larger future studies which will assess the efficacy of these strains in a broader patient population in respect of autism and related neurological disorders.
CannaPacific will house the genetic stock and assist in the development of NTI's exclusively licensed Dolce varietal strains within CannaPacific's Northern NSW cultivation facility.
CannaPacific is licensed and permitted by the Australian Government (Office of Drug Control) to cultivate and research medicinal cannabis which is a requirement to commence sales under the TGA Special Access Scheme.
When commenting on the partnership, Brian Leedman, Chairman of Neurotech International said, “We have previously stated that positive results from our initial trial will pave the way for larger studies to address the unmet need for effective treatments for autism and broader neurological conditions.
“The partnership with CannaPacific allows NTI to ensure that we can maintain momentum with our clinical studies through quality product supply and importantly, maintain and develop our intellectual property base through our exclusive licensing of the Dolce Cann strains”.
Joshua Dennis, CannaPacific CEO added, "CannaPacific is delighted to work with the NTI/Dolce team to assist in providing a GMP supply chain for their unique varieties within our Northern NSW facility.”
“We’re creating an agricultural innovation hub for companies who wish to enter the medicinal cannabis space and leverage our existing cultivation and production facility.”
Terms of the Agreement
The agreement between Neurotech and CannaPacific is for an initial period to 30 June 2021 and does not contain provision for termination prior to this date and is subject to mutual due diligence and the receipt of all relevant regulatory approvals.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.